Alumis, an immunology drug developer on the cusp of Phase 3, will go public Friday in a smaller IPO than it originally projected.
The Bay …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s
New projections pointed to a significant shortage of physicians in the next 10 to 15 years, albeit one smaller than previously anticipated, according to a
Cybin Inc. CYBN has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.)